Group 1 - The company reported a revenue of 1.289 billion RMB for the six months ending June 30, 2025, representing a year-on-year decrease of 10.75% [1] - The company experienced a shareholder loss of 1.04 billion RMB, compared to a profit of 190 million RMB in the same period last year, indicating a significant shift from profit to loss [1] - The basic loss per share was reported at 0.39 RMB [1] Group 2 - The decline in revenue was primarily attributed to a decrease in OPU cycles by approximately 8.3%, an increase in the proportion of IUI patients by about 10.04%, and a reduction in average single-cycle prices by 7% to 8% due to national healthcare adjustments [1] - The traditional delivery volume decreased by about 24% due to lower fertility intentions in China, leading to a reduction in obstetric and related revenues [1] - The number of egg retrieval cycles in Chengdu decreased by 6.1% from 7,571 to 7,111, mainly due to a reduction in new patient numbers and a significant increase in IUI cycle proportions [1] Group 3 - Since the launch of third-generation IVF services in 2024, the company has served over 1,500 patients [2] - The company has introduced prenatal diagnosis and genetic counseling services to support women who conceive through IVF, enhancing the health of newborns [2] - The company has developed an integrated model for IVF and maternity care, leveraging over 70 years of experience in women's and children's healthcare, with a VIP penetration rate of approximately 20.8% at the Sichuan Jinxin Xinan Hospital [2]
锦欣生殖发布中期业绩 股东应占亏损10.4亿元 同比盈转亏